Koronis Pharmaceuticals Announces Late-Breaker Oral Presentation on HIV Therapeutic Candidate KP-1461 at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

James Mullins, Ph.D., to Present Data Supporting In Vivo Drug Activity of KP-1461

Seattle, WA (September 9, 2010) - Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced that clinical trial data demonstrating that the Company’s lead HIV drug, KP-1461, resulted in increased HIV mutations consistent with the Viral Decay Acceleration™ mechanism will be featured in a late-breaker oral presentation by James Mullins, Ph.D., Professor of Microbiology and Medicine at the University of Washington, at the upcoming 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston, MA.

Dr. Mullins will present an oral, slide presentation "First-In-Man Study of the Mutagenic Potential of Nucleoside KP1461 in HIV-1 Infection" on Monday, September 13, at 3:30 p.m., ET at the Boston Convention & Exhibition Center, room 107A, (abstract #H-1170a). The presentation will occur in ICAAC session number 113, titled "Clinical and Translational Studies of HIV Therapeutics and Pathogenesis," 1:30 – 4:00 p.m., ET.

KP-1461 is part of a new class of antiviral therapeutics based on a unique mechanism – Viral Decay Acceleration™ (VDA). Unlike other therapeutics that are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to selectively disrupt the HIV genome by further increasing its naturally high rate of mutation to lethal levels with the goal of eventually causing the collapse of the viral population.

About Koronis

Koronis Pharmaceuticals, Inc., is a privately held biotechnology company developing antiviral therapeutics based on a novel mechanism, Viral Decay Acceleration™ (VDA). The Company's lead product candidate is KP-1461 for the treatment of human immunodeficiency virus (HIV). The Company also has products in development for the treatment of hepatitis C and RSV. For more information, please visit www.koronispharma.com.

# # #

Media Contact:
Julie Rathbun
Rathbun Communications, Inc.
julie@rathbuncomm.com
Tel: (206) 769-9219